Blockade of CTLA-4 increases anti-tumor response inducing potential of dendritic cell vaccineMaryam Esmaily, Farhad Jadidi‐Niaragh, Ali Masjedi et al.|Journal of Controlled Release|2020Cited by 94
PD-L1/PD-1 axis as a potent therapeutic target in breast cancerShima Bastaki, Farhad Jadidi‐Niaragh, Mahzad Irandoust et al.|Life Sciences|2020Cited by 53
Concomitant blockade of A2AR and CTLA‐4 by siRNA‐loaded polyethylene glycol‐chitosan‐alginate nanoparticles synergistically enhances antitumor T‐cell responsesMitra Ghasemi‐Chaleshtari, Farhad Jadidi‐Niaragh, Nasimeh Aghaei Vanda et al.|Journal of Cellular Physiology|2020Cited by 50
Silencing adenosine A2a receptor enhances dendritic cell-based cancer immunotherapyAli Masjedi, Farhad Jadidi‐Niaragh, Armin Ahmadi et al.|Nanomedicine Nanotechnology Biology and Medicine|2020Cited by 49
Targeting the CTLA-4/B7 axes in glioblastoma: preclinical evidence and clinical interventionsMehrdad Fathi, Farhad Jadidi-Niaragh, Seyed‐Mostafa Razavi et al.|Expert Opinion on Therapeutic Targets|2022Cited by 16